ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:IMGN
- CUSIP: 45253H10
- Web: www.immunogen.com
Capitalization:- Market Cap: $553.06 million
- Outstanding Shares: 89,348,000
Average Prices:- 50 Day Moving Avg: $6.00
- 200 Day Moving Avg: $4.11
- 52 Week Range: $1.51 - $8.04
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.15
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $51.8 million
- Price / Sales: 10.68
- Book Value: ($1.88) per share
- Price / Book: -3.29
Profitability:- EBIDTA: ($104,780,000.00)
- Net Margins: -244.76%
- Return on Assets: -60.22%
Debt:- Debt-to-Equity Ratio: -0.58%
- Current Ratio: 3.52%
- Quick Ratio: 3.44%
Misc:- Average Volume: 2.77 million shs.
- Beta: 2.45
- Short Ratio: 5.27
Frequently Asked Questions for ImmunoGen (NASDAQ:IMGN)
What is ImmunoGen's stock symbol?
ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."
How were ImmunoGen's earnings last quarter?
ImmunoGen, Inc. (NASDAQ:IMGN) released its quarterly earnings data on Friday, May, 5th. The company reported ($0.20) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.36) by $0.16. The firm had revenue of $28.70 million for the quarter, compared to the consensus estimate of $16.16 million. The company's revenue was up 45.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.37) EPS. View ImmunoGen's Earnings History.
Where is ImmunoGen's stock going? Where will ImmunoGen's stock price be in 2017?
9 brokerages have issued 1 year price objectives for ImmunoGen's stock. Their predictions range from $1.30 to $12.00. On average, they anticipate ImmunoGen's stock price to reach $6.61 in the next year. View Analyst Ratings for ImmunoGen.
What are analysts saying about ImmunoGen stock?
Here are some recent quotes from research analysts about ImmunoGen stock:
- 1. According to Zacks Investment Research, "ImmunoGen has made significant progress with regard to its lead pipeline candidate, mirvetuximab soravtansine (platinum-resistant ovarian cancer). However, most of the pipeline candidates are in early stages of development and still a long way from entering the market, if at all. Moreover, ImmunoGen has only a limited number of wholly owned candidates in its pipeline. Hence successful development and subsequent approval of its lead candidate, is crucial for growth at ImmunoGen. On the flip side, the company’s collaborations with big healthcare companies not only validate its technology but also provide it with funds in the form of milestone and royalty payments. The company’s shares have outperformed the broader industry so far this year. Notably, estimates have been going down lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters." (7/10/2017)
- 2. Cantor Fitzgerald analysts commented, "IMGN’s announced sale of IMGN529 to Debiopharm for an aggregate of $55 mln provides incremental cash to the company for development of." (5/24/2017)
- 3. Cowen and Company analysts commented, "IMGN presented data from mrive’s Phase I biopsy expansion cohort at SGO." (3/13/2017)
Who are some of ImmunoGen's key competitors?
Some companies that are related to ImmunoGen include Genus plc (GNS), Immunomedics (IMMU), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Cellectis S.A. (CLLS), Albany Molecular Research (AMRI), Arena Pharmaceuticals (ARNA), TG Therapeutics (TGTX), Enanta Pharmaceuticals (ENTA), CRISPR THERAPTC (CRSP), Editas Medicine (EDIT), Spectrum Pharmaceuticals (SPPI), Intellia Therapeutics (NTLA), Wave Life Sciences Ltd (WVE), Mesoblast Limited (MESO), ANI Pharmaceuticals (ANIP), Agenus (AGEN), Cara Therapeutics (CARA) and AC Immune SA (ACIU).
Who are ImmunoGen's key executives?
ImmunoGen's management team includes the folowing people:
- Stephen C. McCluski, Independent Chairman of the Board
- Mark J. Enyedy, President, Chief Executive Officer, Director
- David B. Johnston PhD, Chief Financial Officer, Executive Vice President
- Ellie Harrison, Chief Human Resource Officer, Vice President
- Richard J. Gregory Ph.D., Executive Vice President - Research, Chief Scientific Officer
- John M. Lambert Ph.D., Executive Vice President - Distinguished Research Fellow
- Craig Barrows, Vice President, General Counsel, Secretary
- Peter J. Williams, Vice President - Business Development
- Mark A. Goldberg M.D., Independent Director
- Dean Jonathan Mitchell, Independent Director
Who owns ImmunoGen stock?
ImmunoGen's stock is owned by a number of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.29%), Russell Investments Group Ltd. (0.14%), Northeast Financial Consultants Inc (0.04%), Creative Planning (0.02%), Aperio Group LLC (0.02%) and US Bancorp DE (0.02%). Company insiders that own ImmunoGen stock include Charles Q Morris, Craig Barrows, Daniel M Junius, David Brannon Johnston, Dean J Mitchell, John Lambert, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Institutional Ownership Trends for ImmunoGen.
Who sold ImmunoGen stock? Who is selling ImmunoGen stock?
Who bought ImmunoGen stock? Who is buying ImmunoGen stock?
ImmunoGen's stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Aperio Group LLC and Fisher Asset Management LLC. Company insiders that have bought ImmunoGen stock in the last two years include Craig Barrows, Dean J Mitchell, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Insider Buying and Selling for ImmunoGen.
How do I buy ImmunoGen stock?
Shares of ImmunoGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ImmunoGen's stock price today?
One share of ImmunoGen stock can currently be purchased for approximately $6.19.
MarketBeat Community Rating for ImmunoGen (NASDAQ IMGN)MarketBeat's community ratings are surveys of what our community members think about ImmunoGen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for ImmunoGen (NASDAQ:IMGN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 3 Hold Ratings, 5 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.44) |
| Consensus Price Target: | $6.61 (6.85% upside) |
Analysts' Ratings History for ImmunoGen (NASDAQ:IMGN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/6/2017 | Royal Bank Of Canada | Upgrade | Sector Perform -> Outperform | $5.00 -> $12.00 | High |  |
| 6/28/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $6.00 | High | |
| 6/26/2017 | William Blair | Reiterated Rating | Outperform | | High | |
| 6/19/2017 | Leerink Swann | Reiterated Rating | Outperform | $8.00 -> $11.00 | High | |
| 6/4/2017 | Cantor Fitzgerald | Set Price Target | Hold | $5.00 | Medium | |
| 5/19/2017 | Canaccord Genuity | Set Price Target | Buy | $6.00 | Low | |
| 5/6/2017 | Cowen and Company | Reiterated Rating | Hold | | High | |
| 3/1/2017 | Morgan Stanley | Lower Price Target | Underweight | $2.50 -> $1.30 | N/A | |
| 8/5/2016 | J P Morgan Chase & Co | Set Price Target | Hold | $9.00 -> $5.00 | N/A | |
| 11/10/2015 | Oppenheimer Holdings, Inc. | Reiterated Rating | Buy | $24.00 | N/A | |
(Data available from 7/26/2015 forward)
Earnings History for ImmunoGen (NASDAQ:IMGN)Earnings History by Quarter for ImmunoGen (NASDAQ IMGN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/5/2017 | 3/31/2017 | ($0.36) | ($0.20) | $16.16 million | $28.70 million | View | N/A | |
| 2/17/2017 | Q2 2017 | ($0.39) | ($0.39) | $16.28 million | $13.85 million | View | Listen | |
| 10/28/2016 | Q117 | ($0.38) | ($0.51) | $21.12 million | $7.66 million | View | Listen | |
| 8/4/2016 | Q416 | ($0.39) | ($0.51) | $17.11 million | $7.41 million | View | Listen | |
| 4/29/2016 | Q316 | ($0.31) | ($0.37) | $23.02 million | $19.71 million | View | Listen | |
| 1/29/2016 | Q216 | ($0.36) | ($0.38) | $19.54 million | $18.03 million | View | Listen | |
| 10/27/2015 | Q116 | ($0.35) | ($0.39) | $15.84 million | $14.90 million | View | Listen | |
| 7/31/2015 | Q415 | ($0.34) | ($0.35) | $15.42 million | $12.61 million | View | Listen | |
| 4/24/2015 | Q315 | ($0.25) | ($0.25) | $20.95 million | $11.40 million | View | Listen | |
| 1/30/2015 | Q215 | ($0.06) | $0.16 | $37.30 million | $48.30 million | View | Listen | |
| 10/24/2014 | Q115 | ($0.14) | ($0.26) | $21.80 million | $13.20 million | View | Listen | |
| 8/1/2014 | Q414 | ($0.36) | ($0.31) | $9.72 million | $5.74 million | View | N/A | |
| 4/25/2014 | Q314 | ($0.27) | ($0.44) | $13.28 million | $6.90 million | View | N/A | |
| 1/31/2014 | Q214 | ($0.18) | ($0.29) | $18.16 million | $30.10 million | View | Listen | |
| 10/25/2013 | Q114 | ($0.23) | ($0.13) | $12.10 million | $17.20 million | View | N/A | |
| 8/2/2013 | Q4 2013 | ($0.30) | ($0.26) | $3.44 million | $3.83 million | View | N/A | |
| 4/26/2013 | Q3 2013 | ($0.15) | ($0.02) | $11.94 million | $25.00 million | View | N/A | |
| 1/25/2013 | Q2 2013 | ($0.25) | ($0.29) | $6.02 million | $2.60 million | View | N/A | |
| 10/26/2012 | Q113 | ($0.25) | ($0.30) | $4.10 million | $4.10 million | View | N/A | |
| 8/3/2012 | | ($0.30) | ($0.29) | | | View | N/A | |
| 4/27/2012 | | ($0.26) | ($0.24) | | | View | N/A | |
| 1/27/2012 | | ($0.22) | ($0.17) | | | View | N/A | |
| 10/27/2011 | | ($0.22) | ($0.26) | | | View | N/A | |
| 8/3/2011 | | ($0.24) | ($0.23) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for ImmunoGen (NASDAQ:IMGN)2017 EPS Consensus Estimate: ($1.19)
2018 EPS Consensus Estimate: ($1.53)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.33) | ($0.33) | ($0.33) |
| Q2 2017 | 3 | ($0.35) | $0.17 | ($0.07) |
| Q3 2017 | 3 | ($0.46) | ($0.37) | ($0.41) |
| Q4 2017 | 2 | ($0.40) | ($0.36) | ($0.38) |
| Q1 2018 | 1 | ($0.41) | ($0.41) | ($0.41) |
| Q2 2018 | 1 | ($0.37) | ($0.37) | ($0.37) |
| Q3 2018 | 1 | ($0.37) | ($0.37) | ($0.37) |
| Q4 2018 | 1 | ($0.38) | ($0.38) | ($0.38) |
(Data provided by Zacks Investment Research)
Dividend History for ImmunoGen (NASDAQ:IMGN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ImmunoGen (NASDAQ:IMGN)Insider Ownership Percentage: 6.51%
Institutional Ownership Percentage: 73.91%
Insider Trades by Quarter for ImmunoGen (NASDAQ:IMGN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/15/2016 | Mark Alan Goldberg | Director | Buy | 20,000 | $1.80 | $36,000.00 | |
| 11/8/2016 | Mark J Enyedy | CEO | Buy | 25,000 | $1.83 | $45,750.00 | |
| 11/2/2016 | Craig Barrows | Insider | Buy | 10,000 | $1.71 | $17,100.00 | |
| 11/2/2016 | Richard J Gregory | VP | Buy | 16,600 | $1.78 | $29,548.00 | |
| 2/1/2016 | John Lambert | EVP | Sell | 3,889 | $8.22 | $31,967.58 | |
| 1/8/2016 | Richard J Gregory | VP | Sell | 2,369 | $11.10 | $26,295.90 | |
| 1/4/2016 | Daniel M. Junius | CEO | Sell | 5,416 | $13.17 | $71,328.72 | |
| 1/4/2016 | John Lambert | EVP | Sell | 3,889 | $13.20 | $51,334.80 | |
| 12/1/2015 | Daniel M. Junius | CEO | Sell | 5,416 | $13.11 | $71,003.76 | |
| 12/1/2015 | John Lambert | EVP | Sell | 3,889 | $13.11 | $50,984.79 | |
| 11/27/2015 | Charles Q Morris | VP | Sell | 5,170 | $14.00 | $72,380.00 | |
| 11/17/2015 | Dean J Mitchell | Director | Buy | 10,000 | $12.51 | $125,100.00 | |
| 11/2/2015 | Daniel M. Junius | CEO | Sell | 5,497 | $12.00 | $65,964.00 | |
| 11/2/2015 | John Lambert | EVP | Sell | 3,889 | $11.73 | $45,617.97 | |
| 10/29/2015 | Daniel M. Junius | CEO | Sell | 5,335 | $12.01 | $64,073.35 | |
| 10/1/2015 | John Lambert | EVP | Sell | 3,889 | $9.55 | $37,139.95 | |
| 9/17/2015 | David Brannon Johnston | CFO | Sell | 5,000 | $15.00 | $75,000.00 | |
| 9/1/2015 | Daniel M. Junius | CEO | Sell | 5,416 | $13.15 | $71,220.40 | |
| 9/1/2015 | John Lambert | EVP | Sell | 3,889 | $13.16 | $51,179.24 | |
| 7/1/2015 | Daniel M Junius | CEO | Sell | 5,416 | $14.34 | $77,665.44 | |
| 7/1/2015 | John Lambert | EVP | Sell | 3,888 | $14.34 | $55,753.92 | |
| 6/15/2015 | Nicole Onetto | Director | Sell | 3,211 | $13.86 | $44,504.46 | |
| 6/1/2015 | John Lambert | EVP | Sell | 15,000 | $11.78 | $176,700.00 | |
| 5/7/2015 | Daniel M Junius | CEO | Sell | 1,215 | $8.02 | $9,744.30 | |
| 5/1/2015 | John Lambert | EVP | Sell | 10,000 | $8.32 | $83,200.00 | |
| 11/28/2014 | Charles Q Morris | VP | Sell | 5,240 | $10.40 | $54,496.00 | |
| 3/17/2014 | Daniel Junius | CEO | Sell | 15,000 | $16.40 | $246,000.00 | |
| 2/26/2014 | Charles Morris | VP | Sell | 6,936 | $17.35 | $120,339.60 | |
| 2/20/2014 | Charles Morris | VP | Sell | 13,672 | $17.10 | $233,791.20 | |
| 2/18/2014 | Daniel Junius | CEO | Sell | 15,000 | $16.26 | $243,900.00 | |
| 2/3/2014 | John Lambert | EVP | Sell | 4,375 | $14.90 | $65,187.50 | |
| 1/22/2014 | Charles Morris | VP | Sell | 7,138 | $17.00 | $121,346.00 | |
| 1/10/2014 | Theresa Wingrove | VP | Sell | 6,250 | $15.04 | $94,000.00 | |
| 1/2/2014 | John Lambert | EVP | Sell | 4,375 | $14.53 | $63,568.75 | |
| 12/10/2013 | Daniel Junius | CEO | Sell | 15,000 | $15.11 | $226,650.00 | |
| 12/2/2013 | John Lambert | EVP | Sell | 4,375 | $14.70 | $64,312.50 | |
| 11/26/2013 | Charles Morris | VP | Sell | 12,500 | $13.75 | $171,875.00 | |
| 11/1/2013 | John Lambert | EVP | Sell | 4,375 | $16.41 | $71,793.75 | |
| 9/10/2013 | Gregory D Perry | CFO | Sell | 18,337 | $17.82 | $326,765.34 | |
| 9/3/2013 | Daniel Junius | CEO | Sell | 16,667 | $16.43 | $273,838.81 | |
| 9/3/2013 | John Lambert | EVP | Sell | 4,375 | $16.45 | $71,968.75 | |
| 8/1/2013 | Daniel M Junius | CEO | Sell | 16,667 | $19.21 | $320,173.07 | |
| 8/1/2013 | John Lambert | EVP | Sell | 4,375 | $19.21 | $84,043.75 | |
| 7/11/2013 | James J O'leary | VP | Sell | 35,000 | $19.02 | $665,700.00 | |
| 7/3/2013 | Daniel M Junius | CEO | Sell | 16,667 | $17.31 | $288,505.77 | |
| 7/1/2013 | John Lambert | EVP | Sell | 4,375 | $16.80 | $73,500.00 | |
| 6/3/2013 | John Lambert | EVP | Sell | 11,250 | $17.20 | $193,500.00 | |
| 5/24/2013 | James J O'leary | VP | Sell | 28,900 | $18.11 | $523,379.00 | |
| 5/1/2013 | John Lambert | EVP | Sell | 11,250 | $15.56 | $175,050.00 | |
| 4/11/2013 | James J O'leary | VP | Sell | 31,100 | $17.37 | $540,207.00 | |
| 11/8/2012 | Mark Alan Goldberg | Director | Buy | 3,000 | $11.27 | $33,810.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for ImmunoGen (NASDAQ:IMGN)
Latest Headlines for ImmunoGen (NASDAQ:IMGN)
| Source: |
|
| Date | Headline |
|---|
 | $0.11 Earnings Per Share Expected for ImmunoGen, Inc. (IMGN) This Quarter
www.americanbankingnews.com - July 26 at 8:22 AM |
 | ImmunoGen, Inc. breached its 50 day moving average in a Bearish Manner : IMGN-US : July 24, 2017
finance.yahoo.com - July 26 at 1:08 AM |
 | Why ImmunoGen, Inc. Jumped Higher Today -- The Motley Fool - Motley Fool
www.fool.com - July 24 at 11:37 PM |
| ImmunoGen, Inc. (NASDAQ:IMGN) Cut to Buy at BidaskClub
www.americanbankingnews.com - July 23 at 4:58 PM |
| Is a Beat in the Cards for ImmunoGen (IMGN) in Q2 Earnings?
finance.yahoo.com - July 21 at 4:23 PM |
| ImmunoGen, Inc. to Post Q2 2017 Earnings of $0.17 Per Share, Jefferies Group Forecasts (NASDAQ:IMGN)
www.americanbankingnews.com - July 21 at 8:26 AM |
| Q2 2017 EPS Estimates for ImmunoGen, Inc. (IMGN) Increased by Analyst
www.americanbankingnews.com - July 20 at 8:07 AM |
 | Immunogen Finally Moving 'FORWARD'? - Seeking Alpha
seekingalpha.com - July 19 at 8:55 PM |
| ImmunoGen, Inc. (IMGN) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - July 18 at 10:34 PM |
| ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2017 Financial Results
finance.yahoo.com - July 15 at 2:11 AM |
 | Can ImmunoGen's Lead Pipeline Cancer Candidate Boost Growth?
www.zacks.com - July 14 at 3:47 AM |
| Can ImmunoGen's Lead Pipeline Cancer Candidate Boost Growth?
finance.yahoo.com - July 14 at 3:47 AM |
| Here's Why ImmunoGen, Inc. Shares Exploded 54% Higher in June
finance.yahoo.com - July 10 at 7:47 PM |
| Zacks Investment Research Downgrades ImmunoGen, Inc. (NASDAQ:IMGN) to Sell
www.americanbankingnews.com - July 10 at 12:20 PM |
| ImmunoGen, Inc. (NASDAQ:IMGN) Lifted to "Outperform" at Royal Bank Of Canada
www.americanbankingnews.com - July 9 at 9:24 AM |
| ETFs with exposure to ImmunoGen, Inc. : July 7, 2017
finance.yahoo.com - July 8 at 11:42 AM |
 | ImmunoGen's Turnaround Is 'In Full-Swing' Following ASCO Presentations
feeds.benzinga.com - July 6 at 11:43 AM |
| ImmunoGen, Inc. to Post Q3 2017 Earnings of ($0.46) Per Share, Jefferies Group Forecasts (NASDAQ:IMGN)
www.americanbankingnews.com - July 3 at 7:58 AM |
| Zacks: Brokerages Anticipate ImmunoGen, Inc. (IMGN) Will Post Quarterly Sales of $14.15 Million
www.americanbankingnews.com - July 2 at 10:44 AM |
| ImmunoGen - Reentry Puzzle - Seeking Alpha
seekingalpha.com - July 1 at 1:00 AM |
| ImmunoGen, Inc. (IMGN) Expected to Post Earnings of -$0.40 Per Share
www.americanbankingnews.com - June 30 at 11:16 AM |
 | Immunogen (IMGN): Raising PT After Management Meetings - Jefferies - StreetInsider.com
www.streetinsider.com - June 30 at 5:14 AM |
| ImmunoGen's (IMGN) "Buy" Rating Reiterated at Jefferies Group LLC
www.americanbankingnews.com - June 28 at 11:28 AM |
| Research Analysts Offer Predictions for ImmunoGen, Inc.'s Q2 2017 Earnings (IMGN)
www.americanbankingnews.com - June 28 at 7:32 AM |
| Why ImmunoGen, Inc. Jumped Higher on Monday -- The Motley Fool - Motley Fool
www.fool.com - June 27 at 6:04 PM |
 | BRIEF-ImmunoGen presents data from Phase I study of IMGN779 in acute myeloid leukemia
www.businessinsider.com - June 27 at 5:42 AM |
| Immunogen (IMGN) Presents Data from Phase I Study of IMGN779 ... - StreetInsider.com
www.streetinsider.com - June 27 at 12:41 AM |
| Why ImmunoGen, Inc. Jumped Higher on Monday
www.fool.com - June 26 at 9:23 PM |
| ETFs with exposure to ImmunoGen, Inc. : June 26, 2017
finance.yahoo.com - June 26 at 7:40 PM |
| Immunogen (IMGN) Presents Data from Phase I Study of IMGN779 in AML
www.streetinsider.com - June 26 at 9:25 AM |
| ImmunoGen Presents Data from Phase I Study of IMGN779 in Acute Myeloid Leukemia
finance.yahoo.com - June 26 at 9:25 AM |
| ImmunoGen, Inc. (IMGN) Earns "Outperform" Rating from William Blair
www.americanbankingnews.com - June 26 at 8:34 AM |
| ImmunoGen, Inc. (IMGN) Expected to Earn FY2017 Earnings of ($1.50) Per Share
www.americanbankingnews.com - June 26 at 7:41 AM |
| 5 Best Biotech Stocks of 2017 So Far
www.fool.com - June 25 at 2:04 PM |
| Head-To-Head Survey: Concert Pharmaceuticals (CNCE) & ImmunoGen (IMGN)
www.americanbankingnews.com - June 24 at 12:14 PM |
| ImmunoGen, Inc. (IMGN) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 23 at 8:36 PM |
| Why ImmunoGen, Inc. Jumped Higher for the Second Day in a Row
finance.yahoo.com - June 22 at 10:46 PM |
| Why ImmunoGen, Inc. Jumped Higher for the Second Day in a Row - Motley Fool
www.fool.com - June 22 at 1:15 PM |
| ImmunoGen, Inc. (IMGN) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - June 21 at 10:02 PM |
 | Biopharma Stock Breakouts With Significant Developments and Market Activity
www.prnewswire.com - June 21 at 3:35 PM |
| ImmunoGen (IMGN) Jumps: Stock Rises 10.4%
finance.yahoo.com - June 21 at 3:34 PM |
| Two Bullish Biotech Stocks And A Very Bearish Looking Yelp
finance.yahoo.com - June 21 at 3:34 PM |
 | ImmunoGen Stock Nears Breakout to New Highs (IMGN)
www.investopedia.com - June 20 at 6:45 PM |
| ImmunoGen Stock Nears Breakout to New Highs
finance.yahoo.com - June 20 at 6:45 PM |
| ImmunoGen's (IMGN) Outperform Rating Reiterated at Leerink Swann
www.americanbankingnews.com - June 19 at 8:16 PM |
| ETFs with exposure to ImmunoGen, Inc. : June 16, 2017
finance.yahoo.com - June 16 at 6:45 PM |
| Why Is ImmunoGen (IMGN) Stock Up 131% This Year?
finance.yahoo.com - June 16 at 5:07 AM |
| ImmunoGen, Inc. :IMGN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 11:26 AM |
 | ImmunoGen (IMGN) Up 21.2% Since Earnings Report: Can It Continue? - Nasdaq
www.nasdaq.com - June 7 at 10:09 AM |
| ImmunoGen (IMGN) Up 21.2% Since Earnings Report: Can It Continue?
finance.yahoo.com - June 7 at 10:09 AM |
ImmunoGen (IMGN) Chart for Wednesday, July, 26, 2017
